Palisade Bio

Palisade Bio Palisade Bio (Nasdaq: PALI) is advancing next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases.

We were featured on the The BioHub Podcast by Avetix! It was a great opportunity to discuss the progress of PALI-2108 an...
09/02/2026

We were featured on the The BioHub Podcast by Avetix! It was a great opportunity to discuss the progress of PALI-2108 and what we believe it could mean for the future of ulcerative colitis treatment.

Listen here: https://bit.ly/4h5DgfJ

08/11/2026

“The second quarter marked a decisive transition for Palisade Bio as we completed the regulatory and operational work required to advance PALI-2108 into Phase 2 development,” said JD Finley, Chief Executive Officer of Palisade Bio. Read more: https://bit.ly/4gnvhua

08/10/2026

Palisade Bio today reported financial results for the second quarter ended June 30, 2026, and provided a business update. During the quarter, the Company completed key regulatory and operational activities supporting the planned commencement of the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026. For details: https://bit.ly/4gnvhua

07/13/2026

Attending the Leerink Partners Therapeutics Forum? Palisade's management team will be available for one-on-one investor meetings. For details: https://bit.ly/4ydWy99

07/10/2026

JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer of Palisade Bio, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts. For details: https://bit.ly/4ydWy99

07/01/2026

In parallel with ASCENTRA-UC, Palisade Bio continues to advance development plans for Crohn's disease and currently expects to submit an IND application for ASCENTRA-CD in the second half of 2026, highlighting the broad applicability of PALI-2108 across inflammatory bowel disease indications. For more information: https://bit.ly/3QwuRaV

06/30/2026

ASCENTRA-UC is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase 2 clinical trial expected to enroll approximately 204 patients with moderately to severely active ulcerative colitis across North America and Europe. First patient enrollment is anticipated in the second half of 2026, with primary efficacy results expected in the second half of 2027. Learn more: https://bit.ly/3QwuRaV

06/29/2026

"FDA clearance of our IND application is a significant milestone for Palisade Bio and an important validation of the extensive preclinical, manufacturing and clinical work completed to advance PALI-2108 into Phase 2 development," said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. Read more: https://bit.ly/3QwuRaV

06/29/2026

Palisade Bio today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for PALI-2108, enabling initiation of the global Phase 2 ASCENTRA-UC clinical trial in patients with moderately to severely active ulcerative colitis. For details: https://bit.ly/3QwuRaV

Address

5800 Armada Drive, Suite 210
Carlsbad, CA
92008

Telephone

+18587044900

Website

Alerts

Be the first to know and let us send you an email when Palisade Bio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Palisade Bio:

Shortcuts

Share

Category